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Abstract: Miller Fisher syndrome (MFS) is a triad of total external ophthalmoplegia, ataxia, and 
areflexia, while botulism has the usual clinical presentation of involvement of cranial muscles 
and palsies with blurred vision, diplopia, ptosis, dilated pupils, and facial paralysis, caused by 
a bacterial neurotoxin which attacks proteins involved in presynaptic vesicle release. In this 
report, we needed to make the differential diagnosis between MFS and botulism in a patient 
who presented with acute ophthalmoparesis and a history of diarrhea three days before, which 
started two days after consuming tinned food. Routine laboratory, neurophysiologic, and imag-
ing investigations were normal. A clinical diagnosis of Miller Fisher syndrome was reached by 
anti-ganglioside GQ1B and GM1 Ig G and M antibody investigations which proved positive. 
The patient was treated with intravenous immunoglobulin two weeks after (in the late period) 
the symptoms started and he has recovered completely. Systemic autoimmune diseases should be 
considered in patients with bilateral ophthalmoparesis. As in the present patient, the evaluation 
of specific antibodies helps in the diagnosis and thus early effective treatment is possible.
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Introduction
Miller Fisher syndrome (MFS), first described in 1956, is a triad of total external 
ophthalmoplegia, ataxia, and absent deep tendon reflexes (areflexia). It usually has a 
monophasic course and is a less commonly seen subtype of Guillain Barré syndrome 
(GBS).1 Botulism is caused by a bacterial neurotoxin, typically botulinum toxin type 
A, B, or E produced by Clostridium botulinum. This toxin attacks proteins involved 
in presynaptic vesicle release. The usual clinical presentation is cranial muscle 
involvement, ie, extraocular muscle palsies with blurred vision, diplopia, ptosis, 
dilated pupils, and facial paralysis. Speaking and swallowing problems may occur. 
Eventually flaccid limb paralysis and respiratory dysfunction may develop and the 
disease may be lethal.2
In 1992, acute phase immunoglobulin G (IgG) antibodies to GQ1b ganglioside 
were reported as a highly specific serum marker for MFS.3,4 Over 90% of MFS cases 
have acute phase anti-GQ1b ganglioside antibodies which are particularly associated 
with ophthalmologic disease.5 Miller Fisher syndrome, Birkerstaff brainstem 
encephalitis, and Guillain Barre syndrome have been collectively called “anti-GQ1b 
IgG antibody syndrome”.6 The symptoms seen in MFS are related to cranial nerves 
III, IV, and VI, and it has been suggested by some biochemical studies, and supported 
by immunohistochemical studies, that these cranial nerves contain a considerable 
amount of GQ1b. The serum of affected individuals contains a blocking factor in the Neuropsychiatric Disease and Treatment 2010:6 120
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IgG fraction which acts in a manner similar to some bio-
logic toxins. The distal nerve terminal lacks the blood-nerve 
barrier, and is accessible for circulating antibodies. Thus, the 
cranial nerve findings may be the result of the direct action 
of the antibodies on the neuromuscular junction between the 
cranial nerves and ocular muscles.1,7
There are a number of cases in the literature in which the 
differential diagnosis between botulism and GBS or MFS 
has had to be made very cautiously.2,8–10 In this report, the 
importance of anti-GQ1b antibody titers in the differential 
diagnosis of MFS and botulism was discussed.
Case report
A 16-year-old male presented with a three-day history of 
diarrhea, starting two days after eating tinned beans, followed 
by a hamburger and a toasted sandwich a few hours later. Two 
days after the onset of the diarrhea, he developed fatigue, 
nausea, and vomiting. Acute gastroenteritis therapy was 
started. One day after this, he developed double and blurred 
vision, dizziness, and loss of balance. On admission, his eye 
movements were restricted on both sides, worse on the left, 
pupils were midriatic and unreactive to light, and he had 
bilateral semi-ptosis. Limb power was normal, tendon reflexes 
were decreased, and plantar responses were bilaterally flexor. 
Cerebellar tests, sensory examination, and examination of other 
systems were normal. Routine blood tests including syphilis 
serology, radiological examination including cranial computed 
tomography (CT) and magnetic resonance imaging (MRI) 
scans, and electrocardiogram were normal. Cerebrospinal fluid 
(CSF) studies including cytology were normal; the CSF was 
clear, with normal opening pressure. Electroneurophysiological 
examination, sensory and motor nerve conduction studies, 
F waves, and H reflexes were normal (Tables 1 and 2). On 
repetitive stimulation, no decremental or incremental response 
was observed. The most likely differential diagnosis was 
between botulism and MFS. Stool and serum samples were 
sent for botulism toxin assay, along with antiganglioside GQ1B 
and GM1 Ig G and M antibodies.
After consulting with the infectious diseases department, 
crystallized penicillin treatment plus trivalent botulinum 
anti-toxin against toxins A, B, and E were given. During his 
follow-up in the neurologic intensive care unit, little change 
in his symptoms occurred other than the ophthalmoparesis 
becoming symmetrical.
Two weeks later, an elevated titer of IgG and IgM 
anti-GQ1B was reported. Intravenous immunoglobulin 
(IVIG) therapy (0.4 g/kg/day for five days) was started for 
the treatment of MFS. After the treatment, the eye movements 
improved, ptosis slowly resolved, and diplopia disappeared. 
The tendon reflexes were present but still hypoactive in the 
upper limbs. The patient is still under follow-up by our depart-
ment. Fourteen months after the onset of his symptoms, he 
has no complaints and his neurologic examination is normal 
except for hypoactive tendon reflexes.
Discussion
GBS is usually considered to be the prototype of post-infectious 
neuroimmune disease. Epidemiologic studies have indicated 
previous infection with certain bacteria, eg, Campylobacter 
jejuni and viruses, eg, cytomegalovirus and Epstein–Barr 
viruses.11,12 The syndrome has several pathologic subtypes, the 
most common being multifocal demyelinating polyneuropathy. 
Miller Fisher syndrome is a less commonly seen subtype, with 
a classical triad of total external ophthalmoplegia, ataxia, and 
areflexia.13 Recent research on GBS and the MFS variant has 
focused on the forms mediated by antiganglioside antibodies 
in which correlations have been established between anti-
ganglioside antibodies and specific clinical phenotypes, 
notably between anti-GM1/GD1a antibodies and the acute 
motor axonal variant, and anti-GQ1b/GT1a antibodies and 
MFS.14,15 In GBS the frequency of these antibodies varies 
and has been reported to be 29%–70%, whereas patients 
Table 1 Motor nerve conduction study of the patient
Median  
Right/Left
Ulnar  
Right/Left
Peroneal  
Right/Left
Tibial 
Right/Left
Latency (msec) 3.30/3.40 2.65–6.25–7.30/ 3.45–9.10–10.75/ 4.25–12.90/
(Proximal-distal) 2.30–6.05–7.20 3.55–9.80–10.80 4.70–13.05
Nerve conduction velocity 60.3/54.8 58.3–66.7/ 52.2–57.5/ 46.2/49.1
(m/sec) (Proximal-distal) 56.3–63.4 48.7–61.5
Compound muscle action 7.3–7.2/ 7.2–6.6–7.1/ 4.5–4.3–4.4/ 4.9–5.1/
potential (CMAP/mV) 6.3–6.2 6.3–5.9–6.0 4.3/4.6/4.2 4.6–4.4
(Proximal-distal)
F Wave latency (ms) 24.3/23.5 26.7/25.9 45.7/47.2 49.3/50.7Neuropsychiatric Disease and Treatment 2010:6 121
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with MFS have a much higher frequency of the antibodies, 
probably around 95%.16,17
Botulism is a potentially life-threatening condition caused 
by botulinum neurotoxin that acts against proteins involved in 
presynaptic vesicle release. The neurotoxin is formed during 
the growth of the spore-forming bacterium C. botulinum. It 
can enter the body via the gastrointestinal tract or through 
mucous membranes, ie, the eyes or the respiratory tract. 
The most common form is food-borne botulism and the 
most frequent source is home-canned foods. This form may 
be manifested by gastrointestinal symptoms, ie, nausea, 
vomiting, and constipation, in addition to the general signs 
of botulism discussed below.8,18 After entering the body, the 
neurotoxin is absorbed into the circulation, and reaches motor 
nerve endings where it blocks neurotransmitter release. This 
may occur as rapidly as 12 hours after the entry of the neuro-
toxin inside the body (usually within the first 36 hours). Typi-
cal clinical symptoms include cranial muscle involvement, 
ie, double vision, dilated pupils, slurred speech, dry mouth, 
difficulty in swallowing and speaking, and facial paralysis. As 
the clinical picture progresses, descending flaccid paralysis 
of the limbs and respiratory dysfunction can occur, and may 
be lethal.18,19 The differential diagnosis includes GBS, MFS, 
chemical intoxication, stroke, and other food poisonings. 
Being a potentially lethal condition, the need for a rapid 
diagnosis and appropriate therapy is obvious. Early diagnosis 
is important because antitoxin therapy is most likely to be 
effective when administered early. Recovery time is several 
weeks to months, depending on the amount of toxin ingested 
and the toxin type.18 The main treatment is intensive symp-
tomatic care with respiratory support. IV administration of 
trivalent antitoxin towards A, B, and E toxins can be used to 
neutralize the circulating toxin, but the time of administration 
is important.8,19 In our case, although the patient has presented 
with clinical symptoms suggesting MFS, botulinum toxin 
intoxication could not be ruled out for the following reasons. 
Our patient had complained of diarrhea, after eating tinned 
beans. Later he had developed vomiting, nausea, and acute 
ophthalmoparesis with unresponsive midriatic pupils (which is 
rare in MFS but may occur in botulism). This medical history 
suggested botulism and, because botulism is life-threatening, 
crystallized penicilin treatment in adition to trivalent botulism 
antitoxins against A, B, and E were administered.
In the case reported by Dörr et al the patient had recurrent 
MFS with some characteristics of botulism and normal 
electrophysiologic findings.10 The diagnosis was finally 
made with the help of positive anti-GQ1b antibodies. In the 
case reported by Chadderdon et al the patient presented with 
symptoms suggesting either MFS or botulism, and therefore 
the patient was initially treated for both illnesses. When the 
results of laboratory tests were available, the botulism toxin 
assay was positive for type F toxin, with a culture suggesting 
Clostridium baratii, while anti-GQ1B antibody tests were 
negative. Thus, a diagnosis of botulism was made.19 In our 
patient, just after finishing a course of penicillin treatment, 
the positive anti-GQ1b titer was reported, and thus our final 
diagnosis was MFS. Since the treatment of the two conditions 
is completely different, this case report demonstrates the 
importance of this simple test in the diagnosis and treatment 
of similarly presenting patients.
MFS cases without ataxia but with positive antibody 
titers or anti-GQ1b-positive status with ataxia but no 
opthalmoparesis have also been reported.13,17,20 Our patient did 
not have ataxia or cerebellar findings, but fulfilled the other 
two criteria for MFS. Unreactive pupils are also an unusual 
finding in MFS. There are a number of reports of patients 
with post-infective ophthalmoparesis as well as unreactive 
midriatic pupils. The patient with recurrent MFS described by 
Dörr et al had this feature.14 Chan et al reported a 35-year-old 
female with external ophthalmoplegia, non-reactive pupils, 
and no dysfunction of the other cranial nerves, muscle tone, 
tendon reflexes, muscle power, or the cerebellum. This 
patient also had unresponsive dilated pupils which gradually 
resolved after IVIG treatment. It is postulated that there is an 
immunopathologic involvement of the ciliary ganglion and/or 
denervation supersensitivity of the pupillar sphincter muscles 
in such patients.21 The concept of anti-GQ1b IgG antibody 
syndrome evolved after the description of atypical cases like 
the ones discussed above, with features of MFS, ataxic GBS, 
and other clinical symptoms plus positive anti-ganglioside 
antibodies. These patients seem to share a common antibody 
against GQ1b, and their illness has a relatively mild course.21 
The case described in this report may be accepted as FSH 
because his illness had a mild and benign course.
The mainstay of therapy is careful intensive care and respi-
ratory support when indicated. More specific treatment is also 
available. Clinical trials have shown that plasma exchange 
and IVIG shorten the recovery time if used early.22,23 Plasma 
Table 2 Sensory nerve conduction study of the patient
Median Ulnar Sural
Latency (msec) 2.40/2.30 2.05/2.15 2.60/2.70
Sensory nerve action 
potentials (SNAP/µV)
42.3/48.7 33.7/28.5 17.5/18.3
Nerve conduction  
velocity (m/sec)
58.3/60.8 58.5/55.8 53.8/51.8Neuropsychiatric Disease and Treatment 2010:6
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exchange removes the antibodies in the blood mediating the 
neuropathy, thereby combating the continuous production 
of new autoantibodies. In a monophasic acute illness like 
MFS, this seems to be effective, although complete removal 
of all autoantibodies is impossible.24 IVIG is thought to 
interfere with and prevent the passage of autoimmune T-cells 
into the blood–nerve barrier and also to downregulate the 
blockade of antibody production by B-cells, interfere with 
B-cell proliferaton via blockade of cell surface receptors, 
and prevent the activation of certain subtypes of B-cell. In 
addition, IVIG can affect innate immunity by interrupting 
the steps in the complement activation cascade and 
blocking Fc-receptor mediated activity, which results in 
downregulation of macrophage activity.1,22,25 In conclusion, 
IVIG has numerous modes of activation, which culminate in 
the downregulation of the immune response; many of which 
may be relevant to neuromuscular disorders and immune 
neuropathies.25,26 In our patient, significant improvement of 
the symptoms was observed after IVIG therapy.
In conclusion, systemic autoimmune diseases should 
be considered in patients with bilateral ophthalmoparesis. 
Occasionally botulism is in the differential diagnosis. As in the 
present patient, the evaluation of specific antibodies helps in 
the diagnosis and thus early effective treatment is possible.
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